Home / Treatments / Pacemaker Defib
Pacemaker Defib denials: what the review data shows
Independent reviewers have decided 18 published cases where an insurer denied Pacemaker Defib — and they overturned the insurer 55.6% of the time. A denial for Pacemaker Defib is a starting position, not a final answer.
Published decisions
18
2001–2026
Overturned
55.6%
10 denials reversed
Conditions behind pacemaker defib denials
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Arrhythmia Irregular Heart Rhythm | 6 | 50% |
| Cardiomyopathy | 5 | 80% |
| Cardiac Heart Prob | 4 | 50% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 9 | 44.4% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 9 | 66.7% |
Typical time to a decision
7 days
Most land between 7 and 16 days
Handled as urgent
66.7%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested reimbursement and prospective authorization and coverage for a wearable defibrillator. A recent study found that the management of patients with ventricular arrhythmias and the prevision of sudden cardiac death note that for patients with recent myocardial infarction (MI), newly diagnosed non-ischemic cardiomyopathy (NICM), recent revascularization, myocarditis, and secondary cardiomyopathy are at increased risk of ventricular tachycardia/sudden cardiac arrest (SCA).
The parent of an enrollee has requested authorization and coverage for a portable automated external defibrillator (AED).The 2016 study by Ackerman and colleagues evaluated sudden death in the young and found that home AEDs are important for these patients. Most pediatric cardiologists recommend that families obtain AEDs for their children with long QT and carry them, as AEDs are not always readily available in public. AEDs have been proven to save lives. Survival is greatest when the AED is placed within three minutes of a witnessed collapse.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for a leadless pacemaker. Initial data for leadless pacemakers is promising, with low incidence of complications. However, the pooled data is from small observational studies with relatively limited follow-up periods of less than one year. To date, there have been no randomized controlled trials that have directly compared the safety and efficacy of leadless pacemakers versus transvenous pacing systems, the recommended first-line option for treatment. Furthermore, according to registry data, the life span of currently available leadless pacemakers is estimated to be approximately 10 years.
The enrollee requested authorization and coverage for bioimpedance-derived physiologic cardiovascular analysis, which allows for remote monitoring of the enrollee’s implanted cardiovascular device. The enrollee has a history of dyslipidemia, systolic congestive heart failure, status post cardiac resynchronization therapy defibrillator; and atrial fibrillation with rapid ventricular response, resulting in inappropriate automatic implantable cardioverter defibrillator shocks. The enrollee had two prior accessory pathway ablations for atrial fibrillation-related ventricular tachycardia/ventricular fibrillation, and atrioventricular nodal ablation for recurrent ventricular tachycardia arrest. His systolic function has since normalized. The fluid status monitoring feature on the enrollee’s device previously indicated persistent fluid retention. This, along with transaminitis, has improved.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Pacemaker Defibwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.